Complete Genomics Announces Shipment of Approximately 3,000 Genomes in 2011

OUNTAIN VIEW, Calif. — Complete Genomics, Inc. (Nasdaq:GNOM) today announced that the company delivered approximately 3,000 genomes to its customers in 2011 and is entering 2012 with contracts for approximately 5,800 genomes. The company delivered more than 600 genomes to its customers in the fourth quarter of 2011. The company had earlier projected delivering approximately 900 genomes to its customers in the fourth quarter of 2011 but nearly 300 genomes took longer to move through the pipeline than anticipated and will ship in the first quarter of 2012.

“We are entering 2012 with a strong order book of about 5,800 genomes valued at approximately $28 million,” noted Dr. Clifford Reid, chairman, president, and CEO of Complete Genomics. “We believe that our recent lab expansion will give us the capacity to handle both our current orders and anticipated new sales.”

“We’re pleased that researchers all over the world are recognizing the value of our turnkey service and quality of our sequenced genomes,” Dr. Reid continued. “A recent NatureBiotechnology paper by Lam et al.,1 shows that our sequencing service provides variant data that leads the industry in accuracy.”

In 2011, the company received orders for approximately 8,000 genomes valued at nearly $39 million.

References

1 Lam et al, Platform comparison of whole genome sequencing platforms. Nature Biotechnology (2011)

doi:10.1038/nbt.2065; Published online 18 December 2011.

About Complete Genomics

Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines Complete Genomics’ proprietary human genome sequencing technology with our advanced informatics and data management software. We offer this solution as an innovative, end-to-end, outsourced service, CGA™ Service, and provide customers with data that is immediately ready to be used for genome-based research. Additional information can be found at www.completegenomics.com.

< | >